Avadel's narcolepsy drug Lumryz misses PDUFA date, still under review at FDA

Katherine Lewin

News Reporter

Avadel Pharmaceuticals is still waiting on an answer from the FDA on whether its once-nightly narcolepsy drug Lumryz will be approved to include the pediatric …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Avadel's narcolepsy drug Lumryz misses PDUFA date, still under review at FDA

Katherine Lewin

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Bad trip: How culture conflict and a need for cash nearly broke Lykos

Cigna sues FTC, calling for withdrawal of 'biased, erroneous' PBM report

After landing a key win in a common cancer condition, Pfizer faces a big test in Phase 3

Novartis’ Kisqali snags FDA approval to reduce recurrence in patients with early forms of breast cancer

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

Breaking down silos with a new quantitative approach to drug development

Avadel's nar­colep­sy drug Lum­ryz miss­es PDU­FA date, still un­der re­view at FDA

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Avadel's narcolepsy drug Lumryz misses PDUFA date, still under review at FDA